CJC-1295 DAC vs Mod GRF 1-29
CJC-1295 DAC and Modified GRF 1-29 (Mod GRF) are synthetic analogs of growth hormone-releasing hormone (GHRH) that differ fundamentally in pharmacokinetics and clinical application. CJC-1295 DAC is engineered for sustained GH release through albumin binding, while Mod GRF mimics physiological pulsatile GH secretion.
Structural Modifications
Section titled “Structural Modifications”GHRH 1-29: The Parent Peptide
Section titled “GHRH 1-29: The Parent Peptide”Native GHRH is a 44-amino acid peptide with the biologically active fragment located in the N-terminal 29 residues (GHRH 1-29). This fragment retains full GH-releasing activity.
Modified GRF 1-29 (Mod GRF)
Section titled “Modified GRF 1-29 (Mod GRF)”Mod GRF contains key substitutions to resist DPP-IV degradation:
- Position 2: Ala → D-Ala (prevents aminopeptidase cleavage)
- Position 8: Gly → D-Ala (enhances stability)
- Position 15: Lys → D-Lys (prevents DPP-IV)
- Position 27: Met → Nle (prevents oxidation)
- Position 29: Removed amidation (simplified synthesis)
These modifications extend the half-life from ~7 minutes (native GRF) to ~30 minutes.
CJC-1295 DAC
Section titled “CJC-1295 DAC”CJC-1295 retains the same DPP-IV-resistant backbone as Mod GRF, with an additional modification:
- Drug Affinity Complex (DAC): A reactive lysine derivative that binds covalently to albumin
- Mechanism: Maleimide group reacts with Cys34 of albumin
- Result: Albumin-bound peptide with half-life of ~6–8 days
Pharmacokinetic Comparison
Section titled “Pharmacokinetic Comparison”| Parameter | Mod GRF 1-29 | CJC-1295 DAC |
|---|---|---|
| Half-life | ~30 minutes | ~6–8 days |
| Tmax (GH) | 15–30 minutes | 1–2 hours |
| GH peak | 20–40 ng/mL | 10–20 ng/mL |
| GH elevation duration | 1–2 hours | 6–12 hours |
| Dosing frequency | 1–3× daily | 1–2× weekly |
| IGF-1 elevation | Moderate | Substantial |
Mechanism of Action
Section titled “Mechanism of Action”Both peptides bind the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary:
- Gs-protein activation → adenylyl cyclase stimulation
- cAMP elevation → PKA activation
- Calcium influx → GH vesicle exocytosis
- Gene transcription → sustained GH synthesis
Pulsatile vs Sustained Release
Section titled “Pulsatile vs Sustained Release”Mod GRF produces sharp, pulsatile GH peaks that mimic physiological secretion patterns:
- GH pulses occur 15–30 minutes after injection
- Peak concentrations of 20–40 ng/mL
- Return to baseline within 2 hours
- Preserves the pulsatile signaling important for hepatic IGF-1 production
CJC-1295 DAC produces sustained, blunted GH elevation:
- Gradual GH rise over 1–2 hours
- Peak concentrations of 10–20 ng/mL
- Sustained elevation for 6–12 hours
- Greater cumulative IGF-1 elevation due to prolonged exposure
Receptor Binding and Selectivity
Section titled “Receptor Binding and Selectivity”| Property | Mod GRF 1-29 | CJC-1295 DAC |
|---|---|---|
| GHRHR affinity | High (EC₅₀ ~1 nM) | High (EC₅₀ ~1 nM) |
| Somatostatin receptor interaction | None | None |
| GHS receptor interaction | None | None |
| Selectivity | GHRHR-selective | GHRHR-selective |
| Albumin binding | None | High (covalent) |
Both peptides have equivalent receptor affinity; the difference lies entirely in pharmacokinetics.
GH and IGF-1 Response Profiles
Section titled “GH and IGF-1 Response Profiles”Mod GRF 1-29
Section titled “Mod GRF 1-29”- GH response: Sharp peak, 20–40 ng/mL at 15–30 minutes
- Duration: 1–2 hours
- IGF-1 elevation: 15–25% above baseline
- Pulsatility: Preserved (important for receptor sensitivity)
- Tachyphylaxis: Minimal with intermittent dosing
CJC-1295 DAC
Section titled “CJC-1295 DAC”- GH response: Gradual rise, 10–20 ng/mL sustained over 6–12 hours
- Duration: 6–12 hours
- IGF-1 elevation: 30–50% above baseline
- Pulsatility: Lost (sustained non-physiological release)
- Tachyphylaxis: Potential with chronic dosing
Clinical Applications
Section titled “Clinical Applications”Mod GRF 1-29
Section titled “Mod GRF 1-29”- Growth hormone deficiency: Adjunct to GHRP peptides (Ipamorelin, GHRP-2)
- Anti-aging: Pulsatile GH release preserves receptor sensitivity
- Body composition: Fat loss with minimal water retention
- Research: Standard tool for studying pulsatile GH secretion
CJC-1295 DAC
Section titled “CJC-1295 DAC”- Growth hormone deficiency: Sustained GH elevation for severe GHD
- Muscle wasting: Greater IGF-1 elevation supports anabolism
- Bone density: Sustained IGF-1 promotes osteoblast activity
- Research: Tool for studying sustained GH exposure
Combination Therapy
Section titled “Combination Therapy”Mod GRF + Ipamorelin (Common Protocol)
Section titled “Mod GRF + Ipamorelin (Common Protocol)”The combination of Mod GRF 1-29 with the ghrelin mimetic Ipamorelin produces synergistic GH release:
- Mod GRF: GHRHR agonism → pituitary GH release
- Ipamorelin: GHS-R agonism → additional GH release + appetite stimulation
- Synergy: Dual receptor activation produces greater GH output than either alone
- Dosing: 100–300 µg each, 1–3× daily
CJC-1295 DAC + Ipamorelin
Section titled “CJC-1295 DAC + Ipamorelin”- CJC-1295 DAC: Sustained GH release
- Ipamorelin: Pulsatile GH release
- Result: Both sustained and pulsatile GH elevation
- Concern: May produce excessive IGF-1 elevation; monitoring required
Side Effect Profiles
Section titled “Side Effect Profiles”| Side Effect | Mod GRF 1-29 | CJC-1295 DAC |
|---|---|---|
| Injection site reaction | Rare | Moderate (albumin binding) |
| Flushing | 10–15% | 5–10% |
| Headache | 5–10% | 5–10% |
| Water retention | Minimal | Moderate |
| Carpal tunnel syndrome | Rare | 5–10% (chronic) |
| Joint pain | Rare | 10–15% (chronic) |
| Tachyphylaxis | Minimal | Potential |
CJC-1295 DAC’s sustained IGF-1 elevation increases the risk of side effects associated with chronic GH excess (water retention, joint pain, carpal tunnel).
Dosing Protocols
Section titled “Dosing Protocols”| Parameter | Mod GRF 1-29 | CJC-1295 DAC |
|---|---|---|
| Typical dose | 100–300 µg | 30–60 µg/kg |
| Route | Subcutaneous | Subcutaneous |
| Frequency | 1–3× daily | 1–2× weekly |
| Timing | Bedtime or pre-workout | Any time |
| Cycle length | 3–6 months | 3–6 months |
| Monitoring | IGF-1 levels | IGF-1 levels |
Comparison Table
Section titled “Comparison Table”| Feature | Mod GRF 1-29 | CJC-1295 DAC |
|---|---|---|
| Structure | DPP-IV-resistant GRF | DPP-IV-resistant GRF + DAC |
| Half-life | ~30 minutes | ~6–8 days |
| GH release pattern | Pulsatile | Sustained |
| GH peak | 20–40 ng/mL | 10–20 ng/mL |
| IGF-1 elevation | 15–25% | 30–50% |
| Tachyphylaxis risk | Low | Moderate |
| Side effect profile | Mild | Moderate |
| Dosing frequency | Daily (1–3×) | Weekly (1–2×) |
| Pulsatility preserved | Yes | No |
References
Section titled “References”- Thorner MO, et al. “Growth hormone-releasing hormone treatment.” Endocr Rev 1995;16:176-191.
- Ionescu M, Rheaume C. “CJC-1295, a long-acting growth hormone-releasing hormone analogue.” J Clin Endocrinol Metab 2006;91:2007-2013.
- Teichman SL, et al. “Prolonged stimulation of growth hormone secretion by CJC-1295.” Eur J Endocrinol 2006;155:735-741.
- Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol 1998;139:555-561.
- Camanni F, et al. “Growth hormone-releasing peptides: clinical and preclinical data.” Growth Horm IGF Res 1998;8:129-136.